FOX CHASE CANCER CENTER
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- Conditions
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Interventions
- Drug: Arm ADrug: Arm B
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 117
- Registration Number
- NCT03786692
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Palliative and Oncology Care Intervention: Symptom COACH
- Conditions
- Cancer of Head and Neck
- Interventions
- Other: Evidenced-based symptom management and coping intervention
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT03760471
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT03719898
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
- Conditions
- Breast Cancer Female
- Interventions
- Behavioral: Sexual and Menopausal Health ResourcesBehavioral: Starting the Conversation Video
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 153
- Registration Number
- NCT03624972
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Organ Preservation in Early Rectal Cancer Patients
- Conditions
- Rectal Cancer
- Interventions
- Drug: FOLFOX regimen
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT03548961
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03527108
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Development of Real-time Image-guided Radiotherapy
- Conditions
- Skin CancerBreast CancerLung Cancer
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 159
- Registration Number
- NCT03524248
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
Mychoice: Testing an Interactive mHealth Tool
- Conditions
- ConflictDecisional Conflict
- Interventions
- Behavioral: mychoice
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 257
- Registration Number
- NCT03427177
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Drug: Nivolumab, IV, 240 mg
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03311958
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Procedure: Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03311620
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States